BioPartnering North America

BioPartnering North America

December 22, 2008 11:00 ET

BioPartnering North America (BPN)-Program Goes Live

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Dec. 22, 2008) - Technology Vision Group LLC (TVG) is pleased to announce that the program for the 7th Annual BioPartnering North America (BPN) conference, to be held in Vancouver, B.C., Canada, on February 8-10, 2009 has gone live. For details visit

One of the hallmarks of BPN and reasons for its continued success is its innovative and informative program which annually addresses the latest trends affecting the biotech industry today combined with a strong group of leading industry figures as speakers.

Highlights of this year's program include five BioPartnering Leadership Sessions, where senior executives and industry leaders will address cutting edge themes of interest to the life science community in a number of panel discussions. Leadership Session #2 scheduled on Monday, February 9, offered by Ferghana, is titled: What To Do When Catastrophe Comes Knocking: Fold,Fight, Partner, or M&A (Buy/Sell or Merge)? Ask the "Five Tops": A panel of seasoned industry experts in the following fields will give their views on the circumstances that affect how executives should understand and respond to realistic strategy options: (1) top analyst; (2) top lawyer; (3) top biotech investor; (4) top industry observer; and (5) top deal-doer.

Four industry workshops by leading service providers will also offer one-hour discussions on unique topics in an interactive environment. 114 presenting companies from around the world will showcase their products and partnering goals and five pharmaceutical companies will give pharma presentations. meeting scheduler is now open

In a turbulent world economy, forming partnerships is more important than at any time in the history of BPN. BPN attendees will have access to, the leading life science conference partnering tool. lets attendee's pre-schedule meetings in advance of the event, prospect attendees, and use effective time-management tools to create the optimal conference experience and make the best use of time onsite. Presenting companies may also submit a short video to that can be viewed in a dedicated area by all attendees, letting presenting companies promote themselves in advance of the event in a dynamic and engaging manner. BPN 2008 attendees enjoyed a 40% increase in the number of meetings scheduled.

"Best Partnering Meeting in North America," states Susan Kopp, Idenix Pharma.

Register for BPN now

Register for BPN now at and save CAD $450 (Pounds Sterling 238 / US $367) off the general registration rate.

Pharmaceutical companies may also be eligible to receive two registrations for the price of one! Certain restrictions apply. Contact for details.

Other special registration rates also available for government and academic affiliations, visit for more details.

Canadian Bursary

Technology Vision Group LLC is strongly committed to the Canadian biotechnology industry, and together with BIOTECanada, has financed scholarships to allow students from across Canada to attend BioPartnering North America (BPN). For details on deadlines and how to apply, please contact Graeme Fraser, BIOTECanada at +1.613.230.5585 x233.

Full details about BioPartnering North America online at:


BioAlberta, BIOTECanada, LifeSciences British Columbia

LifeSciences British Columbia supports and represents the biotechnology, medical device, and greater life sciences community of British Columbia through leadership, advocacy and promotion. BIOTECanada is the national, industry-funded association representing the broad spectrum of biotech constituents in Canada, including emerging, established and related service companies in the health, agricultural, and industrial sectors. BioAlberta is the central voice and the organizing hub for the bioindustry in Alberta. Together, they represent the breadth of annual support for BPN from Canadian life science associations on the regional and national level.

Premium Sponsors


Platinum Sponsors

BC Innovation Council; Italian Trade Commission

Gold Sponsors

Burrill & Company; Farris, Vaughn, Willis & Murphy Barristers and Solicitors; Pfizer; Ferghana Partners Group; Cooley Godward Kronish LLP

Silver Sponsors

Bristol-Myers Squibb; Merck & Co., Inc.; Merck Frosst; Procter & Gamble Health Care; Anapharm; Roche; Crucell; Novartis; State of Illinois Canada Office; Novartis

Conference Sponsors

Genome British Columbia

Media Supporters

BioBusiness; BioCentury; Biotechnology Focus; BioWorld Today; Citigate Dewe Rogerson; European Biopharmaceutical Review; FierceBiotech; MarketWire; Nature Publishing Group; Progress Research and Discovery Magazine


BayBio; BIA; BioMelbourne; and Washington Biotechnology & Biomedical Association (WBBA)

2009 Open House Presenters

Alphora Research Inc.; Ambit Biosciences; Bend Research; Ceapro Inc.; CIRION Clinical Trial Services Inc.; Crucell N.V.; French Trade Commission; ImmunoVaccine Technologies Inc. (IVT); Inimex Pharmaceuticals, Inc.; Italian Trade Commission; Pharmaceutical Profiles Ltd.; Pharmatek Laboratories, Inc.; Piramal Healthcare; Prince Edward Island Business Development Inc.; QSV Biologics Ltd; Silence Therapeutics AG /plc; UK Trade & Investment.

2009 Podium Presenters

AAIPharma Inc.; Advanced Life Sciences; Affibody AB; Agile Therapeutics, Inc.; AIM Therapeutics Inc.; Akesis Pharmaceuticals, Inc.; Alpharma Inc.; Apeiron Biologics Gmbh; ApopLogic Pharmaceuticals, LLC; Apthera, Inc.; Aquinox Pharmaceuticals Inc.; Asterand plc; Avecia Biologics Limited; Bend Research; Biobide S.L.; Biolex Therapeutics, Inc.; Bionor Immuno AS; Bionovo, Inc.; BioWisdom Ltd.; Calibrant Biosystems, Inc; Cellzome Inc; Centre for Drug Research and Development; CoMentis, Inc.; Critical Pharmaceuticals Ltd; Cynvec; Cytovance Biologics, Inc.; Diosynth Biotechnology, Inc.; Eurand International S.p.A.; Eureka Therapeutics, Inc.; GMD PharmaSolutions; Hospira, Inc.; Hungarian Investment and Trade Development Agency (ITD Hungary); Innate Pharma; Inovio Biomedical Corporation; International Stem Cell Corporation; Jerini AG; KAI Pharmaceuticals Inc.; Lorus Therapeutics; metanomics Health GmbH; MiCardia; Micromet, Inc.; Migco Pharmaceuticals Ltd.; Modigene Inc.; Nektar Therapeutics; NeoMPS SA; Neotropix, Inc.; Nerites Corporation; Newron Pharmaceuticals SpA; Novacta Biosystems Limited; Numerate, Inc.; Office of Biomedical Advanced Research and Development Authority (BARDA); Oncogenex Technologies Inc.; Oncolytics Biotech Inc.; PARI Pharma; Protalix Biotherapeutics; Proteos, Inc.; PRUDENTAS LLC; Redpoint Bio; Rules-Based Medicine, Inc.; Sandoz GmbH; Selvita sp. z o.o.; SemBioSys Genetics Inc.; Signum Biosciences; Sirona Biochem; SkyePharma plc; Speciality European Pharma Limited; Stem Cell Therapeutics; Stromedix; Summit plc; SuppreMol GmbH; TAU Therapeutics; Transcept Pharmaceuticals; Transdel Pharmaceuticals, Inc.; University of Manitoba; Vakzine Projekt Management GmbH; Victory Pharma; Vifor Pharma Aspreva; Viron Therapeutics Inc.; VLST Corporation; Welichem Biotech Inc.; WEX Pharmaceuticals Inc.; Xenome Ltd.; YM BioSciences Inc.; Zymeworks.

Contact Information